Aprea’s APR-1051 Shows Early Efficacy in Endometrial Cancer; Raises $5.6M via Private Placement

Aprea Therapeutics (APRE) announced on January 29, 2026, that its drug candidate APR-1051 demonstrated clinical activity in endometrial cancer patients during early trials, prompting the company to secure $5.6 million in a private placement to fund further development. The financing, led by existing institutional investors, priced at-market and includes warrants. Proceeds will support ongoing Phase 1/2 studies evaluating APR-1051 as a monotherapy and in combination regimens. The compound targets mutant p53 reactivation, a mechanism implicated in multiple solid tumors. Aprea reported preliminary data showing tumor reduction in heavily pretreated patients. The company plans to present updated results at a medical conference in Q2 2026. APRE shares closed at $1.82 on Nasdaq prior to the announcement.